



Hydra Biosciences to Present at the 17th Annual BIO CEO & Investor Conference

February 2, 2015 – Cambridge, MA – [Hydra Biosciences](#), a leader in the field of Transient Receptor Potential (TRP) channel modulation, today announced that Russell Herndon, President and CEO, will provide a company update at the 17th Annual BIO CEO & Investor Conference in New York City. The presentation is on Feb.10, 2015, at 10:45 a.m. in the Park South room at the Waldorf Astoria hotel.

The [BIO CEO & Investor Conference](#) is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Each year, the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions and educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings and networking opportunities.

About Hydra Biosciences

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Mass. that develops drugs to treat pain, inflammation, anxiety and other diseases using its expertise in novel ion channels. Hydra Biosciences' proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: www.hydrabiosciences.com.

###

Corporate:

Russell Herndon
President and CEO
617-494-5230 x3352

Media Contact:

LaVoieHealthScience
Kristina Coppola
617-374-8800, Ext. 105
kcoppola@lavoiehealthscience.com